FacebookTwitterGoogle+RedditEmail

FDA Commissioner Hamburg Appointed WHO Deputy?

by

Many had high hopes for the FDA when Margaret Hamburg was confirmed as Commissioner in 2009 because of her public health background. But she swiftly moved to loosen conflict of interest rules governing those who can serve on FDA expert advisory panels, claiming it was too hard to find experts without Pharma financial links.

Her move followed a Philadelphia Inquirer reporter’s revelations that child psychiatrist Jorge Armenteros, a paid consultant to AstraZeneca, was on an FDA committee voting on–any guesses?–the AstraZeneca drug Seroquel.

Last month, more questions about embedded conflicts of interest at the FDA were raised when Commissioner Hamburg appointed Robert Califf, M.D., chancellor of clinical and translational research at Duke University, as the next FDA Deputy Commissioner for Medical Products and Tobacco despite a thicket of conflicts of interest. It was one of her last official acts before announcing her resignation last week.

A disclosure statement on the website of Duke Clinical Research Institute says “Robert M. Califf, MD, reports receiving research grant support from Novartis Pharmaceuticals, Johnson & Johnson/Scios, Lilly, Merck, and Schering Plough, and consulting fees from Annenberg, Aterovax, Bayer/Ortho McNeil, BMS, Boehringer Ingelheim, GSK, WebMd/theheart.org, Johnson and ohnson/Scios, Kowa Research Institute, McKinsey & Company, Medtronic, Merck, Novartis Pharmaceuticals, Sanofi Aventis, and Schering Plough, and has an equity position with NITROX, LLC.”

In disclosure information for a 2013 article in Circulation, Dr. Califf’s also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche, others companies and equity positions in four medical companies. The medical website Medscape discloses that Dr. Califf “served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech” as well as for Medscape LLC/theheart.org. Portola Pharmaceuticals says Dr. Califf served on the Board of Directors until he was appointed FDA Deputy Commissioner for Medical Products and Tobacco.

Appearing on PBS with Susan Dentzer after Vioxx was withdrawn because of its links to thousands of heart attacks and stroke, Dr. Califf said, “Merck played by the rules from everything that I’ve seen.” He also said, “many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study.” What?

This is not the first time Dr. Califf’s extreme Pharma links have not blocked him from consideration for a top government post. He was up for Dr. Hamburg’s job itself, reported Reutersalong with three others. At the time, some medical voices asked how someone who helps drug companies market their products could possibly be considered as the nation’s chief watchdog over unsafe medications.

Industry conflicts at the FDA cost lives. Recently Senators Joe Manchin (D-W.Va.) and David Vitter (R-La.) questioned whether the FDA’s approval last year of the synthetic opioid Zohydro stemmed from pay-to-play meetings with Big Pharma who allegedly shelled out thousands to meet with regulators. Big Pharma’s hand in the opioid epidemic which causes 17,000 overdose deaths a year in the U.S. is well documented and egregious.

Commissioner Hamburg’s appointment of Dr. Califf amounts to a sad legacy. It also suggests the FDA is no longer even making a pretense at policing industry/government conflicts of interest.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:
Weekend Edition
July 01, 2016
Friday - Sunday
Andrew Levine
Hillary: Ordinarily Awful or Uncommonly Awful?
Rob Urie
Liberal Pragmatism and the End of Political Possibility
Pam Martens
Clinton Says Wall Street Banks Aren’t the Threat, But Her Platform Writers Think They are
Michael Hudson
The Silence of the Left: Brexit, Euro-Austerity and the T-TIP
Ismael Hossein-Zadeh
Marx on Financial Bubbles: Much Keener Insights Than Contemporary Economists
Evan Jones
Ancillary Lessons from Brexit
Jason Hirthler
Washington’s Not-So-Invisible Hand: It’s Not Economics, It’s Empire
Mike Whitney
Another Fed Fiasco: U.S. Bond Yields Fall to Record Lows
Aidan O'Brien
Brexit: the English and Welsh Enlightenment
Jeremy R. Hammond
How Turkey’s Reconciliation Deal with Israel Harms the Palestinians
Margaret Kimberley
Beneficial Chaos: the Good News About Brexit
Phyllis Bennis
From Paris to Istanbul, More ‘War on Terror’ Means More Terrorist Attacks
Dan Bacher
Ventura Oil Spill Highlights Big Oil Regulatory Capture
Ishmael Reed
OJ and Jeffrey Toobin: Black Bogeyman Auctioneer
Ron Jacobs
Let There Be Rock
Ajamu Baraka
Paris, Orlando and Turkey: Displacing the Narrative of Western Innocence
Pete Dolack
Brexit Will Only Count If Everybody Leaves the EU
Robert Fantina
The First Amendment, BDS and Third-Party Candidates
Julian Vigo
Xenophobia in the UK
David Rosen
Whatever Happened to Utopia?
Andre Vltchek
Brexit – Let the UK Screw Itself!
Jonathan Latham
107 Nobel Laureate Attack on Greenpeace Traced Back to Biotech PR Operators
Steve Horn
Fracked Gas LNG Exports Were Centerpiece In Promotion of Panama Canal Expansion, Documents Reveal
Robert Koehler
The Right to Bear Courage
Colin Todhunter
Pro-GMO Spin Masquerading as Science Courtesy of “Shameful White Men of Privilege”
Eoin Higgins
Running on Empty: Sanders’s Influence on the Democratic Party Platform
Binoy Kampmark
Who is Special Now? The Mythology Behind the US-British Relationship
Mark B. Baldwin
Russia to the Grexit?
Andrew Wimmer
Killer Grief
Manuel E. Yepe
Sanders, Socialism and the New Times
Franklin Lamb
ISIS is Gone, But Its Barbarity Still Haunts Palmyra
Mark Weisbrot
A Policy of Non-Intervention in Venezuela Would be a Welcome Change
Matthew Stevenson
Larry Cameron Explains Brexit
Cesar Chelala
How Tobacco Became the Opium War of the 21st Century
Joseph Natoli
How We Reached the Point Where We Can’t Hear Each Other
Andrew Stewart
Skip “Hamilton” and Read Gore Vidal’s “Burr”
George Wuerthner
Ranching and the Future of the Sage Grouse
Thomas Knapp
Yes, a GOP Delegate Revolt is Possible
Gilbert Mercier
Democracy Is Dead
Missy Comley Beattie
A Big F#*K You to Voters
Charles R. Larson
Mychal Denzel Smith’s “Invisible Man, Got the Whole World Watching: a Young Black Man’s Education”
Barbara Nimri Aziz
Four Morning Ducks
David Yearsley
Where the Sidewalk Ends: Walking the Bad Streets of Houston’s Super-Elites
Christopher Brauchli
Educating Kansas
Andy Piascik
The Hills of Connecticut: Where Theatre and Life Became One
FacebookTwitterGoogle+RedditEmail